B
ESPR

Bailard’s Esperion Therapeutics ESPR Stock Holding History

Bailard’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-71,000
Closed -$177K – 488
2019
Q4 		$177K Buy
+71,000
New +$3.19M 0.01% 506
2018
Q2 		– Sell
-53,300
Closed -$320K – 523
2018
Q1 		$320K Buy
+53,300
New +$3.91M 0.02% 404

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bailard's ESPR Position: Q3 2021 in Review

Bailard sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 10,000 shares — an estimated $212K sold.

Bailard first reported a position in ESPR in Q4 2015 and held it in 19 quarters. The position peaked at $5.36M in Q4 2019. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

  • Bailard reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bailard sold 10,000 Esperion Therapeutics shares in Q3 2021, an estimated $212K.
  • Bailard first reported a position in Esperion Therapeutics in Q4 2015 and held it in 19 quarters.
  • Bailard's Esperion Therapeutics position peaked at $5.36M in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Bailard's 13F filing for Q3 2021, filed 15 Nov 2021.